Zhitong Finance App News, Xinhua Pharmaceutical (000756.SZ) issued an announcement. Recently, the company received the “Drug Registration Certificate” for sacubatl valsartan tablets (hereinafter referred to as “this product”) approved and issued by the State Drug Administration. This product is used in adult patients with chronic heart failure (NYHA grade II-IV, LVEF ≤ 40%) with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure. This product can replace angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor antagonists (ARB) and can be used in combination with other heart failure treatment drugs.

Zhitong Finance App News, Xinhua Pharmaceutical (000756.SZ) issued an announcement. Recently, the company received the “Drug Registration Certificate” for sacubatl valsartan tablets (hereinafter referred to as “this product”) approved and issued by the State Drug Administration. This product is used in adult patients with chronic heart failure (NYHA grade II-IV, LVEF ≤ 40%) with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure. This product can replace angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor antagonists (ARB) and can be used in combination with other heart failure treatment drugs.